Please enable Javascript and disable ad blockers

Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Pentixapharm Holding AG Stock

Price

Target price

/ Tradegate WKN: A40AEG / Name: Pentixapharm Holding / Stock / ? /

Latest predictions

Best running prediction

Your prediction

Pentixapharm Holding AG Stock

We can see a decrease in the price for Pentixapharm Holding AG. Compared to yesterday it has lost -€0.048 (-2.580%).

What does Pentixapharm Holding do?

Pros and Cons of Pentixapharm Holding AG in the next few years

Pros

?

C******** o* t** e**********

?

G***** c******* t* c**********

?

B****

Cons

?

M***** P*******

?

S********** s********

?

W********* I********* f** t** n*** y****

Tell us your opinion to access the 'Wisdom of the Crowds'

Register To Post

News

EQS-News: Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026

EQS-News: Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026

EQS-News: Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026

0

EQS-News: Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program

EQS-News: Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program

EQS-News: Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program

0

EQS-News: Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension

EQS-News: Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension

EQS-News: Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension

0